BREAST CANCER

NCCN updates guidelines to include sacituzumab govitecan as a first-line treatment for metastatic triple-negative breast cancer, enhancing patient options.

New clinical data reveals Bria-IMT's potential to significantly extend survival in patients with heavily pretreated metastatic breast cancer, offering hope for better outcomes.

A virtual collaborative care model enhances mental health support in oncology, improving patient outcomes and addressing care disparities in underserved populations.

A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in patients with untreated metastatic triple-negative breast cancer.

Practice-changing 2025 breast cancer trial updates spotlight giredestrant, tucatinib maintenance, and ribociclib in key subtypes, boosting disease control with manageable safety.

The FDA reviews gedatolisib, a promising treatment for advanced breast cancer, aiming to enhance patient outcomes with innovative combination therapies.

EMA validates T-DXd and pertuzumab for first-line HER2-positive metastatic breast cancer, potentially transforming treatment standards in the EU.

Atossa Therapeutics advances Z-endoxifen for metastatic breast cancer, showing promise in clinical trials and receiving FDA approval to proceed with studies.

Breakthroughs in breast cancer treatment in 2025 highlight FDA approvals and innovative therapies, enhancing outcomes for HR+, HER2–, and TNBC patients.

FDA designates T-DXd as breakthrough therapy for high-risk HER2-positive early breast cancer, promising improved survival rates over current treatments.

Liquid biopsy enhances risk assessment for patients with neoadjuvant therapy-resistant tumors, guiding treatment decisions and improving survival outcomes.

Sacituzumab govitecan shows improved survival and quality of life in advanced triple-negative breast cancer, outperforming standard chemotherapy in recent trials.

Sacituzumab govitecan shows a favorable safety profile in treating untreated triple-negative breast cancer, with manageable adverse effects compared to chemotherapy.

A groundbreaking blood test for early breast cancer detection shows exceptional accuracy, outperforming traditional mammography, especially in dense breast tissue.

FDA approves T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.

A new trial shows promising results for combining niraparib and dostarlimab in treating triple-negative breast cancer with BRCA mutations.

Premenopausal women with early breast cancer favor GnRHa therapy for fertility preservation during chemotherapy, with varying acceptance based on age and hormone receptor status.

A RAD51-based assessment identifies HER2-negative breast cancer patients likely to benefit from olaparib, enhancing treatment selection and outcomes.

Real acupuncture significantly enhances cognitive health in breast cancer survivors, outperforming usual care and showing promise over sham treatments.

New data from the TRIFOUR trial show that nadunolimab plus chemotherapy offers no significant survival benefit in metastatic triple-negative breast cancer.

Imlunestrant shows significant progression-free survival benefits in advanced breast cancer, offering a promising treatment option for patients.

Giredestrant combined with everolimus significantly improves progression-free survival in advanced ER+, HER2-negative breast cancer after CDK4/6 inhibitors.

Gedatolisib combined with fulvestrant shows significant progression-free survival benefits in advanced breast cancer, regardless of prior treatment duration.

Long-term PALLAS study results reveal no survival advantage for palbociclib plus endocrine therapy over endocrine therapy alone in breast cancer patients.